Hepatocellular Carcinoma
Conditions
Brief summary
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Interventions
BIOLOGICALZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
BIOLOGICALBevacizumab
15 mg/kg administered intravenously Q3w
BIOLOGICALSintilimab
200 mg administered intravenously Q3w
Sponsors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Fully understand the study and voluntarily sign the informed consent form. * 18-75 years of age; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1； * Life expectancy ≥ 12 weeks.
Exclusion criteria
* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival，PFS | through study completion, up to 2 year | defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first. |
Countries
China
Contacts
Primary ContactBo Liu
Outcome results
None listed